| abstract |
The present invention provides certain compounds, methods for their preparation, pharmaceutical compositions comprising the compounds, and their use in the treatment of human or animal disorders. The compounds of the present invention serve as modulators of the interaction between receptors for terminal glycated substances (RAGE) and their ligands (eg terminal glycated substances (AGE), S100 / calgranulin / EN-RAGE, β-amyloid and amphoterin). Useful and useful as treatment, treatment, control or adjunct treatment of disease in humans caused by RAGE. Such diseases or conditions include acute and chronic inflammation, development of end-stage diabetes complications (eg, increased vascular permeability, nephropathy, atherosclerosis and retinopathy), development of Alzheimer's disease, erection Dysfunction and tumor invasion and tumor metastasis are included. |